600211.SHG Tibet Rhodiola Pharmaceutical Holding Co
- Market cap
- CNY 13.1B
- P/E
- 12.8x
- P/B
- 3.40x
- ROE
- 27.9%
- Dividend yield
- 4.71%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600211.SHG undervalued?
Graham number600211.SHG trades 39.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tibet Rhodiola Pharmaceutical Holding Co fundamental analysis
No fundamental analysis for Tibet Rhodiola Pharmaceutical Holding Co yet.
Tibet Rhodiola Pharmaceutical Holding Co stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tibet Rhodiola Pharmaceutical Holding Co
Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceutical products in China and internationally. The company offers modern Tibetan Medicines, including Nodikang capsules and granules, snow mountain golden arhat pain relief film, and ten-flavor Tida capsules; modern Chinese medicines, such as children Shuangqing granules, lipid clearing capsules, ginseng and zhi capsules, puyu capsules, and epilepsy flat film; and recombinant human brain natriuretic peptide …
Full company profileTibet Rhodiola Pharmaceutical Holding Co financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tibet Rhodiola Pharmaceutical Holding Co annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 797M | 916M | 1.03B | 1.26B | 1.37B | 2.14B | 2.55B | 3.13B | 2.81B | 2.95B | 2.90B |
| Gross Profit | 608M | 675M | 821M | 1.05B | 1.18B | 1.91B | 2.35B | 2.98B | 2.64B | 2.74B | 2.68B |
| Operating Income | 190M | 213M | 244M | 351M | 472M | 257M | 465M | 899M | 1.16B | 925M | 1.07B |
| EBITDA | 292M | 357M | 321M | 431M | 549M | 341M | 547M | 978M | 1.24B | 1.00B | 1.12B |
| Net Income | 198M | 230M | 216M | 312M | 418M | 209M | 370M | 801M | 1.05B | 938M | 1.03B |
| EPS | 0.75 | 0.75 | 0.66 | 0.96 | 1.30 | 0.65 | 1.15 | 2.48 | 3.26 | 2.91 | 3.21 |
| Balance Sheet | |||||||||||
| Total Assets | 2.29B | 2.33B | 2.53B | 2.77B | 2.94B | 3.80B | 4.10B | 4.59B | 4.75B | 6.27B | 6.26B |
| Total Liabilities | 1.63B | 285M | 275M | 320M | 356M | 1.16B | 1.07B | 1.21B | 795M | 2.10B | 2.26B |
| Shareholders' Equity | 661M | 2.04B | 2.25B | 2.44B | 2.58B | 2.63B | 3.01B | 3.34B | 3.92B | 3.80B | 3.71B |
| Cash & Short-term Investments | 373M | 315M | 529M | 830M | 783M | 1.30B | 1.93B | 2.38B | 2.62B | 3.45B | 3.41B |
| Total Debt | 787M | - | 500K | 500K | 10.4M | 539M | 488M | 501M | 272M | 841M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 250M | 91.5M | 289M | 490M | 428M | 367M | 837M | 1.08B | 995M | 1.03B | - |
| Capital Expenditure | 9.64M | 608M | 23.4M | 49.0M | 221M | 426M | 102M | 21.7M | 37.6M | 16.0M | 22.9M |
| Free Cash Flow | 241M | -517M | 266M | 441M | 207M | -59.0M | 735M | 1.04B | 957M | 1.01B | 1.05B |
| Ratios | |||||||||||
| ROE | 30.0% | 11.2% | 9.6% | 12.8% | 16.2% | 7.9% | 12.3% | 23.9% | 26.8% | 24.7% | 27.9% |
| ROA | 8.7% | 9.9% | 8.5% | 11.3% | 14.2% | 5.5% | 9.0% | 17.5% | 22.1% | 15.0% | 16.5% |
| Net Profit Margin | 24.9% | 25.1% | 21.0% | 24.9% | 30.4% | 9.8% | 14.5% | 25.6% | 37.5% | 31.8% | 35.7% |
| Debt to Equity | 1.19x | - | 0.00x | 0.00x | 0.00x | 0.20x | 0.16x | 0.15x | 0.07x | 0.22x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Tibet Rhodiola Pharmaceutical Holding Co dividends
- Dividend yield
- 4.71%
- Forward dividend
- 2.02 CNY
- Payout ratio
- 65.8%
- Ex-dividend date
- Sep 15, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 618M | 1.92 | 65.8% |
| 2024 | CNY 504M | 1.56 | 47.9% |
| 2023 | CNY 483M | 1.50 | 60.3% |
| 2022 | CNY 98.2M | 0.30 | 26.5% |
| 2021 | CNY 126M | 0.39 | 60.5% |
| 2020 | CNY 188M | 0.58 | 44.9% |
| 2019 | CNY 66.5M | 0.20 | 21.3% |
| 2018 | CNY 69.2M | 0.21 | 32.1% |
| 2017 | CNY 79.4M | 0.26 | 34.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Apr 30, 2024.
Who owns Tibet Rhodiola Pharmaceutical Holding Co
- Insiders 60.64%
- Institutions 2.12%
- Public & others 37.25%
- Shares outstanding 322M
- Free float 130M
Tibet Rhodiola Pharmaceutical Holding Co company profile
- Company name
- Tibet Rhodiola Pharmaceutical Holding Co
- Ticker
- 600211.SHG
- ISIN
- CNE000000ZW7
- Exchange
- Shanghai Stock Exchange
- Listed since
- Jul 1, 1999
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 671
- Fiscal year end
- December
- Address
- Lhasa Economic and Technological Development Zone, Lhasa, China, 850000
- Phone
- 86 891 6836521
- Website
- xzyy.cn
About Tibet Rhodiola Pharmaceutical Holding Co
Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceutical products in China and internationally. The company offers modern Tibetan Medicines, including Nodikang capsules and granules, snow mountain golden arhat pain relief film, and ten-flavor Tida capsules; modern Chinese medicines, such as children Shuangqing granules, lipid clearing capsules, ginseng and zhi capsules, puyu capsules, and epilepsy flat film; and recombinant human brain natriuretic peptide for injection. It also provides isosorbide mononitrate sustained-release tablets; and oxygen rhodiola rosea moisturizing essence, secret recipe fragrance powder packet, rhodiola rosea, and Yuan Yang rhodiola rosea moisturizing essence products. In addition, the company offers biopharmaceuticals, traditional Chinese medicine, and chemical drugs for various fields, such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines. The company was founded in 1999 and is headquartered in Lhasa, China.
Tibet Rhodiola Pharmaceutical Holding Co management
4- Mr. Yuan Dong GuoGM & Director · born 1972
- Mr. Jun ChenFinancial Director & Accounting Supervisor · born 1978
- Ms. Lan LiuDeputy GM & Secretary of the Board · born 1969
- Mr. Yong Guo YuanDeputy General Manager · born 1978